CIK 0001831828 · Pharmaceutical Preparations (SIC 2834) · Nasdaq · incorporated in DE · fiscal year ends 12/31
| FY2025 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|
| Net income (USD) | -89.1 M | -32.6 M | -53.4 M | |
| Diluted EPS (USD/shares) | -4.66 | -3.35 |
| Filed | Form | Description | Period |
|---|---|---|---|
| 2026-09-17 | 4 | 4 | 2026-09-15 |
| 2026-09-15 | 8-K | 8-K items 7.01,8.01,9.01 | 2026-09-15 |
| 2026-09-14 | 4 | 4 | 2026-09-11 |
| 2026-09-04 | 4 | 4 | 2026-09-02 |
| 2026-09-02 | 144 | 144 | |
| 2026-08-14 | SCHEDULE 13G/A | SCHEDULE 13G/A | |
| 2026-08-12 | 4/A | 4/A | 2026-07-07 |
| 2026-08-12 | 4/A | 4/A | 2026-06-23 |
| 2026-08-12 | 4/A | 4/A | 2026-05-12 |
| 2026-08-10 | 10-Q | 10-Q | 2026-06-30 |
| 2026-08-10 | 8-K | 8-K items 2.02,9.01 | 2026-08-10 |
| 2026-08-07 | SCHEDULE 13G | SCHEDULE 13G | |
| 2026-08-05 | 4 | 4 | 2026-08-03 |
| 2026-08-05 | 3 | 3 | 2026-08-03 |
| 2026-07-30 | SCHEDULE 13G/A | SCHEDULE 13G/A | |
| 2026-07-09 | 4 | 4 | 2026-07-07 |
| 2026-07-09 | 8-K | 8-K items 5.02 | 2026-07-09 |
| 2026-07-07 | 8-K | 8-K items 8.01 | 2026-07-07 |
| 2026-06-24 | 4 | 4 | 2026-06-23 |
| 2026-06-23 | 144 | 144 | |
| 2026-06-02 | 8-K | 8-K items 8.01 | 2026-06-02 |
| 2026-05-26 | 8-K | 8-K items 5.07 | 2026-05-21 |
| 2026-05-26 | 4 | 4 | 2026-05-21 |
| 2026-05-26 | 4 | 4 | 2026-05-21 |
| 2026-05-26 | 4 | 4 | 2026-05-21 |
Forms on file (last 1,000): 4 193, 8-K 63, 144 32, 3 31, SC 13G/A 18, 10-Q 17, SC 13D/A 13, 424B5 12. Source: SEC EDGAR, as filed; this page is public data and not investment advice.
GET https://store.agentexchange.work/gw/filings/company?ticker=VERA (0.002 USD), /gw/filings/filings?ticker=VERA&form=8-K, /gw/filings/facts?ticker=VERA&concept=Revenues, full-text /gw/filings/search?q=.... Pay per call in USDC (x402) or with a 19 USD card key for 1,000 calls. Catalogue · llms.txtUpdated from EDGAR within 30 minutes of a filing. Agent Exchange